









Markets
/
Stocks
/
nasdaq-nvs
/

Novartis AG

NVS

View Detailed Chart

114.900USD

-1.730-1.48%

Market hours （ET）Quotes delayed by 15 min

222.43BMarket Cap

17.30P/E TTM



Novartis AG

114.900

-1.730-1.48%

Overview Company Financials

Financials

Intraday

30m

Today

-1.48%

5 Days

-2.60%

1 Month

-5.05%

6 Months

+9.69%

Year to Date

+18.08%

1 Year

+2.65%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 10 analysts

HOLD

Current Rating

114.024

Target Price

-2.73%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

172

Total

Median

Average

Company name

Ratings

Analysts

Novartis AG

NVS

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Amgen Inc

AMGN

Alnylam Pharmaceuticals Inc

ALNY

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(7)

Neutral(4)

Buy(2)

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.694

Sell

RSI(14)

45.781

Neutral

STOCH(KDJ)(9,3,3)

59.923

Neutral

ATR(14)

2.001

Low Volatility

CCI(14)

-23.877

Neutral

Williams %R

68.462

Sell

TRIX(12,20)

-0.096

Sell

StochRSI(14)

39.904

Neutral

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

117.038

Sell

MA10

116.290

Sell

MA20

118.959

Sell

MA50

117.578

Sell

MA100

113.880

Buy

MA200

109.514

Buy

News

Pharma Giant Flexes Financial Muscle — Novartis Posts Strong Earnings, Announces $10 Billion Buyback

TradingKey - In the early hours of July 17 (U.S. Eastern Time), Swiss pharmaceutical giant Novartis (NVS.US) released its Q2 2025 earnings report and announced a new share buyback program of up to $10 billion.

TradingKeyThu, Jul 17

NFL signs Novartis as first pharmaceutical partner-source

NEW YORK, March 13 (Reuters) - The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based firm Novartis NOVN.S, a league source told Reuters on Thursday.

ReutersThu, Mar 13

US appeals court lifts pause on generic version of Novartis' Entresto

WASHINGTON, Jan 16 - Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' NOVN.S blockbuster heart-failure drug Entresto after a U.S. appeals court ended a temporary pause on MSN's launch.

ReutersThu, Jan 16

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Ticker SymbolNVS

CompanyNovartis AG

CEODr. Vasant (Vas) Narasimhan, M.D.

Websitehttps://www.novartis.com/